CN100346802C - Chinese medicine composition for preventing and treating hysteromyoma and mammary gland swelling, regulating menstruation and beautifying - Google Patents
Chinese medicine composition for preventing and treating hysteromyoma and mammary gland swelling, regulating menstruation and beautifying Download PDFInfo
- Publication number
- CN100346802C CN100346802C CNB2004100097592A CN200410009759A CN100346802C CN 100346802 C CN100346802 C CN 100346802C CN B2004100097592 A CNB2004100097592 A CN B2004100097592A CN 200410009759 A CN200410009759 A CN 200410009759A CN 100346802 C CN100346802 C CN 100346802C
- Authority
- CN
- China
- Prior art keywords
- flos
- chinese medicine
- medicine composition
- mammary gland
- angelicae sinensis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses a Chinese medicinal compound which is prepared from the following raw medicinal materials of weight portions: 12 to 38 of angelica, 1 to 16 of safflower, 1 to 14 of rose, 1 to 8 of Chinese rose, 1 to 20 of white hyacinth bean flower, 1 to 19 of cockscomb flower, 1 to 15 of pangolin scale, 1 to 12 of cowherb seed, 1 to 22 of chrysanthemum, 1 to 10 of sophora flower and 1 to 10 of prepared liauorice root, and can be capsules, a tablets, pills, an oral medicinal liquid, etc. With the functions of promoting blood circulation, benefiting qi and nourishing blood, dredging channels and dissipating blocking masses, the present invention can be used for curing hysteromyoma and mammary gland tumescence and has the effects of regulating and stopping menstruation and beautifying and nursing face.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition, is a kind of Chinese medicine composition that is used to prevent and treat hysteromyoma, mammary gland enlargement specifically, also has the effect of adjusting meridian and stopping leukorrhea, looks improving and the skin nourishing simultaneously.
Background technology
Hysteromyoma is the abbreviation of leiomyoma of uterus, is modal female sex organ benign tumor, is mainly in middle-aged women.Generation that it is generally acknowledged hysteromyoma may be in close relations with estrogen, and the part exists high concentration estrogen easily to stimulate the smooth muscle fiber hypertrophy.The size of hysteromyoma is not proportional with symptom, different clinical manifestations is arranged usually: the general non-evident sympton of (1) Subserous myoma owing to the muscular tumor growth site is different.(2) intramural myoma is at hour non-evident sympton, muscular tumor the grow up visible menorrhagia in back, menostaxis and lower abdomen bearing down, leucorrhoea grow in quantity, even can cause infertile.(3) fleshy polyp can cause menorrhagia, menostaxis, the caused anemia that the course of disease is long, infertile and easily miscarriage.(4) the cervix uteri muscular tumor can cause frequent micturition, urine retention, constipation etc.
In general the treatment of hysteromyoma divides operation and non-operative treatment, operative treatment comprises myomatectomy, panhysterectomy etc., non-operative treatment multiselect hormone medicine, as: danazol, gossypol etc., or take tcm syndrome differentiation and treatment, and it is generally acknowledged primary disease Shu “ mass in the abdomen in theory of Chinese medical science " category, how to cause; treat based on regulating qi-flowing for activating stagnancy, promoting blood circulation and breaking stagnation eliminating stagnation by the stagnation of QI, blood stasis, phlegm-damp, as: GUIZHI FULING JIAONANG and GONGLIUQING capsule etc.
Children's was born back 3～5 days, no matter be girl baby or boy baby, the phenomenon of breast swelling appears in the meeting that has, be generally the bilateral symmetric property enlargement, size differs in size as Semen Viciae fabae to Ovum Coturnicis japonicae, also can secrete a small amount of milk sometimes, and quantity does not wait from several to 1～2 milliliter, generally giving birth to the most obvious in the time of 8～18 days, 2～3 weeks back Lock-out in back, minority also just disappeared possibly in lasting about 1 month.The phenomenon of this mammary gland enlargement is a kind of normal physiological phenomenon, is called the enlargement of physiological mammary gland, and this is subjected to for neonate can to disappear voluntarily in 2～3 weeks due to the influence of parent estrogen before death, need not treat, and must guard against extruding in order to avoid infect.
Summary of the invention
The purpose of this invention is to provide a kind of Chinese medicine composition that is used to prevent and treat hysteromyoma, mammary gland enlargement and adjusting meridian and stopping leukorrhea, looks improving and the skin nourishing.
The invention provides a kind of Chinese medicine composition that is used to prevent and treat hysteromyoma, mammary gland enlargement and adjusting meridian and stopping leukorrhea, looks improving and the skin nourishing.It is made up of active ingredient and/or pharmaceutically acceptable carrier, it is characterized in that: made by following raw materials by weight proportions: Radix Angelicae Sinensis 1-50 part, Flos Carthami 1-50 part, Flos Rosae Rugosae 1-50 part, Flos Rosae Chinensis 1-50 part, Flos Semen Lablab Album 1-50 part, Flos Celosiae Cristatae 1-50 part, Squama Manis 1-50 part, Semen Vaccariae 1-50 part, Flos Chrysanthemi 1-50 part, Flos Sophorae 1-50 part, Radix Glycyrrhizae Preparata 1-50 part.
Wherein preferred, Radix Angelicae Sinensis 12-38 part, Flos Carthami 1-16 part, Flos Rosae Rugosae 1-14 part, Flos Rosae Chinensis 1-8 part, Flos Semen Lablab Album 1-20 part, Flos Celosiae Cristatae 1-19 part, Squama Manis 1-15 part, Semen Vaccariae 1-12 part, Flos Chrysanthemi 1-22 part, Flos Sophorae 1-10 part, Radix Glycyrrhizae Preparata 1-10 part.
Wherein said Flos Semen Lablab Album can substitute with Spica Prunellae; Radix Angelicae Sinensis can substitute with Radix Salviae Miltiorrhizae.
Chinese medicine composition of the present invention can be made various common formulations together with its effective ingredient and/or acceptable accessories, as capsule, tablet, pill, oral liquid etc.
The present invention by animal experiment and clinical observation have promoting blood circulation to restore menstrual flow, benefiting qi and nourishing blood, clots absorbing collateral dredging, the effect of the long-pending piece that dissipates, available prevention and treatment hysteromyoma, mammary gland enlargement, and can adjusting meridian and stopping leukorrhea, looks improving and the skin nourishing.
Specific embodiment
Embodiment 1: the preparation of capsule of the present invention
Take by weighing following materials of weight proportions medicine: Radix Angelicae Sinensis 35g, Flos Carthami 50g, Flos Rosae Rugosae 50g, Flos Rosae Chinensis 50g, Flos Semen Lablab Album 45g, Flos Celosiae Cristatae 50g, Squama Manis 1g, Semen Vaccariae 10g, 45 parts of Flos Chrysanthemis, Flos Sophorae 45g, Radix Glycyrrhizae Preparata 35g, carry out preliminary working with Radix Angelicae Sinensis, Flos Carthami, Flos Rosae Rugosae, Flos Rosae Chinensis, Flos Semen Lablab Album, Flos Celosiae Cristatae, Squama Manis, Semen Vaccariae, Flos Chrysanthemi, Flos Sophorae, Radix Glycyrrhizae Preparata; The medicine that then processing is cooked drops into multi-function extractor, the water that adds 3-8 times of drug weight, heat and decoct boiling back 25 minutes to 3 hours after-filtration of slow fire for the first time, the water that adds for the second time 3-6 times of drug weight, back 25 minutes to 3 hours after-filtration seethe with excitement, the same for the third time, after three times three filtered medicine liquid being dropped into vacuum concentrator concentrates, after concentrating, extract to drop in the jacketed pan and carry out water evaporates, put into the heated drying case again, temperature in the drying baker is controlled between the 40-70 degree, take out after 5-8 hour, planar, again through pulverizing, sieve, add adjuvant (starch, PVP etc.) make granule, above-mentioned granule pack in the hungry area softgel shell capsule.
Embodiment 2: the preparation of tablet of the present invention
Take by weighing following materials of weight proportions medicine: Radix Angelicae Sinensis 45g, Flos Carthami 5g, Flos Rosae Rugosae 15g, Flos Rosae Chinensis 15g, Flos Semen Lablab Album 10g, Flos Celosiae Cristatae 25g, Squama Manis 10g, Semen Vaccariae 1g, Flos Chrysanthemi 25g, Flos Sophorae 15g, Radix Glycyrrhizae Preparata 15g, carry out preliminary working with Radix Angelicae Sinensis, Flos Carthami, Flos Rosae Rugosae, Flos Rosae Chinensis, Flos Semen Lablab Album, Flos Celosiae Cristatae, Squama Manis, Semen Vaccariae, Flos Chrysanthemi, Flos Sophorae, Radix Glycyrrhizae Preparata; The medicine that then processing is cooked drops into multi-function extractor, the water that adds 3-8 times of drug weight, heat and decoct boiling back 25 minutes to 3 hours after-filtration of slow fire for the first time, the water that adds for the second time 3-6 times of drug weight, back 25 minutes to 3 hours after-filtration seethe with excitement, the same for the third time, after three times three filtered medicine liquid are dropped into vacuum concentrator and concentrate, after concentrating, extract to drop in the jacketed pan and carry out water evaporates, put into the heated drying case again, temperature in the drying baker is controlled between the 40-70 degree, take out after 5-8 hour, planar, again through pulverizing, sieve, add adjuvant (starch, PVP etc.) making granule, is slabbing after compressing.
Embodiment 3: the preparation of pill of the present invention
Take by weighing following materials of weight proportions medicine: Radix Angelicae Sinensis 1g, Flos Carthami 35g, Flos Rosae Rugosae 35g, Flos Rosae Chinensis 15g, Flos Semen Lablab Album 50g, Flos Celosiae Cristatae 15g, Squama Manis 10g, Semen Vaccariae 35g, Flos Chrysanthemi 50g, Flos Sophorae 50g, Radix Glycyrrhizae Preparata 50g, carry out preliminary working with Radix Angelicae Sinensis, Flos Carthami, Flos Rosae Rugosae, Flos Rosae Chinensis, Flos Semen Lablab Album, Flos Celosiae Cristatae, Squama Manis, Semen Vaccariae, Flos Chrysanthemi, Flos Sophorae, Radix Glycyrrhizae Preparata; The medicine that then processing cooked is pulverized, is sieved, and sterilizes again, put in right amount at last the Mel of perfecting mix the back pill.
Embodiment 4: the preparation of oral liquid of the present invention
Take by weighing following materials of weight proportions medicine: Radix Angelicae Sinensis 50g, Flos Carthami 10g, Flos Rosae Rugosae 45g, Flos Rosae Chinensis 35g, Flos Semen Lablab Album 50g, Flos Celosiae Cristatae 35g, Squama Manis 50g, Semen Vaccariae 50g, Flos Chrysanthemi 50g, Flos Sophorae 35g, Radix Glycyrrhizae Preparata 45g, Radix Angelicae Sinensis, Flos Carthami, Flos Rosae Rugosae, Flos Rosae Chinensis, Flos Semen Lablab Album, Flos Celosiae Cristatae, Squama Manis, Semen Vaccariae, Flos Chrysanthemi, Flos Sophorae, Radix Glycyrrhizae Preparata are boiled decocting three times, filter, merging filtrate, concentrate, add sweeting agent Mel and diluent water and make oral liquid.
Embodiment 5: the preparation of capsule of the present invention
According to embodiment 1 described method, difference is to select following materials of weight proportions medicine for use: Radix Angelicae Sinensis 12g, Flos Carthami 1g, Flos Rosae Rugosae 14g, Flos Rosae Chinensis 1g, Spica Prunellae 20g, Flos Celosiae Cristatae 19g, Squama Manis 5g, Semen Vaccariae 12g, Flos Chrysanthemi 1g, Flos Sophorae 10g, Radix Glycyrrhizae Preparata 1g.
Embodiment 6: the preparation of tablet of the present invention
According to embodiment 2 described methods, difference is to select following materials of weight proportions medicine for use: Radix Angelicae Sinensis 38g, Flos Carthami 16g, Flos Rosae Rugosae 1g, Flos Rosae Chinensis 8g, Flos Semen Lablab Album 1g, Flos Celosiae Cristatae 1g, Squama Manis 15g, Semen Vaccariae 1g, Flos Chrysanthemi 22g, Flos Sophorae 1g, Radix Glycyrrhizae Preparata 10g.
Embodiment 7: the preparation of pill of the present invention
According to embodiment 3 described methods, difference is to select following materials of weight proportions medicine for use: Radix Angelicae Sinensis 24g, Flos Carthami 14g, Flos Rosae Rugosae 4g, Flos Rosae Chinensis 6g, Flos Semen Lablab Album 12g, Flos Celosiae Cristatae 14g, Squama Manis 10g, Semen Vaccariae 12g, Flos Chrysanthemi 20g, Flos Sophorae 5g, Radix Glycyrrhizae Preparata 5g.
Embodiment 8: the preparation of oral liquid of the present invention
According to embodiment 4 described methods, difference is to select following materials of weight proportions medicine for use: Radix Salviae Miltiorrhizae 23g, Flos Carthami 10g, Flos Rosae Rugosae 12g, Flos Rosae Chinensis 3g, Spica Prunellae 12g, Flos Celosiae Cristatae 10g, Squama Manis 5g, Semen Vaccariae 12g, Flos Chrysanthemi 13g, Flos Sophorae 2g, Radix Glycyrrhizae Preparata 2g.
Below set forth the effect of this Chinese medicine composition by test.
Experimental example 1:
1 material
1.1 medicine and reagent
BUPIXIAO PIAN is provided by Shenyang Traditional Chinese Medicine Factory of northeast pharmacy group company.Estradiol benzoate injection, the 9th pharmaceutical factory provides by Shanghai.Progesterone injection is provided by fairy house pharmaceutical factory of Zhejiang medicine limited company.Estradiol (E2) radioimmunoassay kit, Chinese Academy of Medical Sciences nuclear medicine technology center, Science and Technology Ltd. of Concord Hospital provide.Progesterone (P), follicle stimulating hormone (FSH) are measured box, are provided by the Beijing North biotechnology research.
1.2 animal
The Wistar female rats, body weight 160-200g, Chinese Academy of Sciences animal provides.
2 methods
Get 60 of rats, be divided into 6 groups at random, be respectively normal control group, model control group, three dosage groups of the present invention (0.5g/kg, 1g/kg, 2g/kg), BUPIXIAO PIAN 1.04g/kg group, 10 every group.Normal control treated animal intramuscular injection normal saline 0.1ml/ only, every day 1 time, continuous 30 days, other each intramuscular injection estradiol benzoate 0.5mg/kg, every day 1 time, continuous 25 days, intramuscular injection Progesterone 4mg/kg subsequently, every day 1 time, continuous 5 days.From modeling the 1st day, each organized administration 1ml/100g, every day 1 time, and continuous 33 days, after the last administration 1 hour, pentobarbital sodium 30mg/kg anesthesia, abdominal aortic blood, separation of serum is exempted from method mensuration serum E with putting
2, P, FSH.Respectively at measuring first pair of breast diameter of every rat chest and height of nipples value with precision vernier callipers before and after the administration.
3 results
3.1 influence (seeing Table 1) to breast diameter and height of nipples
The influence of table 1 pair breast diameter and height of nipples (x ± s)
| Group | Dosage (g/kg) | Breast diameter | Height of nipples | ||
| Before the treatment | After the treatment | Before the treatment | After the treatment | ||
| Normal group model control group breast addiction disappears and organizes of the present invention group | —— —— 1.04 0.5 1 2 | 0.96± 0.12 1.07± 0.32 1.02± 0.41 0.99± 0.33 1.08± 0.32 1.02± 0.42 | 1.03± 0.17 1.96± 0.20## 1.68± 0.26 *1.73± 0.21 *1.64± 0.26 *1.66± 0.33* | 1.72± 0.31 1.69± 0.22 1.68± 0.23 1.70± 0.29 1.71± 0.25 1.71± 0.31 | 1.75±0.26 2.13± 0.16## 1.87±0.26 * 1.92± 0.13 ** 1.83±0.21 * 1.80± 0.19 ** |
Compare with model control group
*P＜0.05,
*P＜0.01
Compare ##P＜0.01 with the normal control group
As seen from the above table, the obvious enlargement of animal injection estrogen rear udder attachment, breast diameter and height of nipples all significantly increase than normal group, and BUPIXIAO PIAN can suppress the breast swelling that estrogen causes, the present invention's three dosage groups breast diameter and height of nipples all obviously reduce (P＜0.05, P＜0.01).
3.2 influence (seeing Table 2) to sex hormone level
The influence of table 2 pair cyclomastopathy rat gonadal hormone (n=10, x ± s)
| Group | Dosage (g/kg) | E 2 (pg/ml) | P (ng/ml) | FSH (mIU/ml) |
| Normal group model control group breast addiction disappears and organizes of the present invention group | —— —— 1.04 0.5 1 2 | 4.58±7.52 23.56±12.21## 18.75±14.32 18.71±14.62 16.25±13.54 10.21±5.32 ** | 7.62±5.84 2.11±0.54## 2.52±0.98 2.41±0.65 2.46±1.41 3.26±1.29 * | 1.39±0.48 0.98±0.33# 1.62±0.44 ** 1.61±0.39 ** 1.63±0.52 ** 1.59±0.34 ** |
Annotate: compare with model control group,
*P＜0.05,
*P＜0.01.
As seen from the above table, hyperplasia of mammary gland model group and normal group compare, serum estradiol (E
2) content significantly increases (P＜0.01), progesterone (P) and follicle stimulating hormone (FSH) content significantly reduce (P＜0.05, P＜0.01), after BUPIXIAO PIAN and the present invention's treatment, follicle stimulating hormone content all obviously increases, and the BUPIXIAO PIAN high dose can also make that estradiol content obviously reduces, progesterone content obviously raises.
4. conclusion
Can be reached a conclusion by this test, the present invention has good preventive and therapeutic effect to the experimental rat cyclomastopathy.
Experimental example 2:
1 data and method
1.1 object of study and grouping
Select Symptomatic patients with uterine myoma 120 examples, make a definite diagnosis 33～55 years old age through gynecologial examination and B ultrasonic.Main suit's excessive menstruation 97 examples wherein, dysmenorrhea 72 examples have lower abdomen to weigh down 85 examples that expand.Be divided into 2 groups at random, be respectively treatment group of the present invention and matched group, two groups of patient's age, body weight, the inferior credits by statistics of motherhood are analysed, and difference does not have significance.
1.2 method
Of the present invention group: take oral liquid of the present invention from first day of menstrual cycle, every day 3 times, each 23g took 6 months continuously.
The mifepristone group: every day 1 time, each 12.5mg takes from first day of menstrual cycle, takes continuously 6 months.
Regularly did B ultrasonic before two groups of patient treatments and during the treatment in every month and measure the volume of uterus and hysteromyoma, blood drawing have a blood test routine, hepatic and renal function, survey routine urinalysis are observed clinical symptoms, medicine side reaction, and are advised patient's period in a medicine person if discomfort is arranged with examining.
1.3 curative effect judging standard:
Muscular tumor volume (V)=A*B*C* π/6
(A, B, C represent the radius of the three-dimensional radial line of muscular tumor respectively)
Muscular tumor volume-diminished rate (%)=(1-V
x/ V
0) * 100%
(V
0The volume of muscular tumor before the representative treatment, V
xThe muscular tumor volume that records after the representative treatment)
To myomatosis, the volume that calculates maximum muscular tumor as a result of.
2 results
2.1 treatment back hysteromyoma dwindles degree (seeing Table 1)
Uterus and hysteromyoma volume situation (cm before and after table 1 treatment
3, x ± s)
| Group | Uterine volume | The hysteromyoma volume | Hysteromyoma dwindles percentage rate | |
| Of the present invention group of mifepristone group | After treating before the treatment after the front treatment for the treatment of | 382.17±113.21 298.13± 102.54 ** 376.25±127.81 278.15± 113.84 ** | 142.31±79.82 89.73±46.25 ** 138.24±88.21 74.56±33.12 ** | —— 0.423±0.154 —— 0.457±0.105 |
With treatment is relatively preceding on the same group,
*P＜0.01
As seen from the above table, treat back uterine volume and muscular tumor volumes and before the treatment significant difference (P＜0.01) is arranged more all on the same group for two groups; Two groups of tumor body minifications compare there was no significant difference (P＞0.05).
2.2 doing well,improving situation after the medication
The medication of treatment group played menstrual blood volume in the second month and reduces gradually, and the dysmenorrhea symptom all disappears, and lower abdomen weighs down to expand and obviously alleviates.Menstrual blood volume also reduces gradually after the matched group medication, and the dysmenorrhea symptom all disappears, and lower abdomen weighs down to expand and obviously alleviates.
2.3 side reaction situation
Matched group 6 examples have slight hectic fever sense, and sense was felt sick when 2 example beginnings were taken medicine in several days, and the back of continuing to take medicine disappears.Do not see lesions of liver and kidney; Treatment group patient of the present invention sees obvious adverse reaction in the end.
3. conclusion
The present invention has the obvious treatment hysteromyoma, improves the effect of dysmenorrhea symptom, and does not have side reaction.
Claims (5)
1, a kind of Chinese medicine composition that is used to prevent and treat hysteromyoma, mammary gland enlargement and energy adjusting meridian and stopping leukorrhea, it is made up of active ingredient and pharmaceutically acceptable carrier, it is characterized in that: made by following raw materials by weight proportions: Radix Angelicae Sinensis 1-50 part, Flos Carthami 1-50 part, Flos Rosae Rugosae 1-50 part, Flos Rosae Chinensis 1-50 part, Flos Semen Lablab Album 1-50 part, Flos Celosiae Cristatae 1-50 part, Squama Manis 1-50 part, Semen Vaccariae 1-50 part, Flos Chrysanthemi 1-50 part, Flos Sophorae 1-50 part, Radix Glycyrrhizae Preparata 1-50 part.
2, Chinese medicine composition according to claim 1 is characterized in that: made by following raw materials by weight proportions: Radix Angelicae Sinensis 12-38 part, Flos Carthami 1-16 part, Flos Rosae Rugosae 1-14 part, Flos Rosae Chinensis 1-8 part, Flos Semen Lablab Album 1-20 part, Flos Celosiae Cristatae 1-19 part, Squama Manis 1-15 part, Semen Vaccariae 1-12 part, Flos Chrysanthemi 1-22 part, Flos Sophorae 1-10 part, Radix Glycyrrhizae Preparata 1-10 part.
3, Chinese medicine composition according to claim 1 and 2, wherein said Flos Semen Lablab Album can substitute with Spica Prunellae.
4, Chinese medicine composition according to claim 1 and 2, wherein said Radix Angelicae Sinensis can substitute with Radix Salviae Miltiorrhizae.
5, Chinese medicine composition according to claim 1 and 2, it is capsule, tablet, pill, oral liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100097592A CN100346802C (en) | 2004-11-08 | 2004-11-08 | Chinese medicine composition for preventing and treating hysteromyoma and mammary gland swelling, regulating menstruation and beautifying |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100097592A CN100346802C (en) | 2004-11-08 | 2004-11-08 | Chinese medicine composition for preventing and treating hysteromyoma and mammary gland swelling, regulating menstruation and beautifying |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1772074A CN1772074A (en) | 2006-05-17 |
| CN100346802C true CN100346802C (en) | 2007-11-07 |
Family
ID=36759325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100097592A Expired - Fee Related CN100346802C (en) | 2004-11-08 | 2004-11-08 | Chinese medicine composition for preventing and treating hysteromyoma and mammary gland swelling, regulating menstruation and beautifying |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100346802C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102488763B (en) * | 2011-12-28 | 2014-01-08 | 江苏普诺生生物科技有限公司 | Composition with functions of treating dysmenorrhoea and beautifying |
| CN104491066A (en) * | 2014-12-07 | 2015-04-08 | 苏州普罗达生物科技有限公司 | Flower composition for increasing immunity |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1170582A (en) * | 1996-07-15 | 1998-01-21 | 鲍树伟 | Chinese drug for curing and preventing mastosis and its preparing method |
| CN1416849A (en) * | 2001-11-05 | 2003-05-14 | 张高军 | Externally applied medicine for treating mastopathy and its prepn |
| CN1541678A (en) * | 2003-11-07 | 2004-11-03 | 英 徐 | Mastoplasia treating medicine |
-
2004
- 2004-11-08 CN CNB2004100097592A patent/CN100346802C/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1170582A (en) * | 1996-07-15 | 1998-01-21 | 鲍树伟 | Chinese drug for curing and preventing mastosis and its preparing method |
| CN1416849A (en) * | 2001-11-05 | 2003-05-14 | 张高军 | Externally applied medicine for treating mastopathy and its prepn |
| CN1541678A (en) * | 2003-11-07 | 2004-11-03 | 英 徐 | Mastoplasia treating medicine |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1772074A (en) | 2006-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100342889C (en) | Chinese medicine for treating gout | |
| CN101584797B (en) | Application of traditional Chinese medicine composition in preparing medicament for treating climacteric syndrome | |
| CN1857690A (en) | Gynecopathy treating preparation and its preparing process | |
| CN100446806C (en) | Xinshenghua oral liquid and its preparation method | |
| CN101073643B (en) | Chinese-medicinal preparation for preventing and treating hypogalactias and and gynecopathy, its production and use | |
| CN1289137C (en) | Medicine for treating mammary gland proliferation, its preparation method and application | |
| CN1765392A (en) | Chinese compound formulation for nourishing blood, regulating menstruation, stopping bleeding to prevent abortion and preparation method thereof | |
| CN1965990A (en) | Medicament for preventing and treating benign hyperplasia of mammary glands in women and preparation process thereof | |
| CN103446500B (en) | Traditional Chinese medicine composition for treating cyclomastopathy, mammary pain and postpartum milk obstruction | |
| CN100346802C (en) | Chinese medicine composition for preventing and treating hysteromyoma and mammary gland swelling, regulating menstruation and beautifying | |
| CN1709288A (en) | Medicinal composition, and its preparing method and use | |
| CN103585573A (en) | Oral medicine for treating hysteromyoma | |
| CN1404867A (en) | Chinese medicine for treating hyperplasia of mammary glands | |
| CN1308032C (en) | Medicinal composition for treating parafunctional metrorrhagia and its preparation method | |
| CN103463276B (en) | Mammary gland hyperplasia treatment drug composition and preparation method thereof | |
| CN1217680C (en) | Repellent mixture for department of gynecology | |
| CN1160089C (en) | Prepn of Xianjia medicine granule for treating hyperprolactin | |
| CN110420278A (en) | It is a kind of for treating the pharmaceutical composition of gynecological disease | |
| CN1850248A (en) | Chinese medicine capsule for treating hyperplasia mammary glands and preparing method | |
| CN1281262C (en) | Chinese medicine for gynaecological tumor and preparation method | |
| CN103705857B (en) | For preventing the Chinese medicine composition of oral cavity radiomucitis | |
| CN102847060A (en) | Traditional Chinese medicine composition for treating uterine myoma and preparation method thereof | |
| CN101361955B (en) | Traditional Chinese medicine combination for treating rheumatism | |
| CN1308031C (en) | Chinese medicine composition for treating biliary tract disease, preparing method and use | |
| CN105853796A (en) | Medicine composition for treating habitual abortion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |